Skip to main content
Ocumension Therapeutics logo

Ocumension Therapeutics — Investor Relations & Filings

Ticker · 1477 ISIN · KYG674111011 LEI · 5493000USURI3SIL4Z85 HKEX Manufacturing
Open in API
Filings indexed 460 across all filing types
Latest filing 2021-09-06 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 1477

About Ocumension Therapeutics

http://www.ocumension.com

Ocumension Therapeutics is an ophthalmic pharmaceutical platform company dedicated to the research, development, and commercialization of first-in-class or best-in-class therapeutics. The company focuses on providing comprehensive treatment solutions for Chinese patients suffering from ocular diseases. Ocumension has established a complete ophthalmic drug product line, currently holding 20 drug assets covering both anterior and posterior segments of the eye. Its portfolio addresses major conditions such as chronic non-infectious uveitis, infective and allergic conjunctivitis, and diabetic macular edema. The company employs a strategy combining continuous scientific innovation, independent R&D, and strategic alliances to sustain the supply of innovative products across the ophthalmology field.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 August 2021
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 31 August 2021. It details movements in authorized and issued shares, share options, warrants, and other share-related information. It is addressed to the Hong Kong Exchanges and Clearing Limited and includes confirmations related to securities issuance and compliance with listing rules. The content focuses on share capital changes and securities movements rather than financial performance, earnings, or management commentary. It is a regulatory filing reporting share capital and securities movements as required by the exchange rules, not a financial report or announcement of voting results or management changes. Therefore, it fits best under Regulatory Filings (RNS) as a general compliance and disclosure document related to securities movements under exchange rules.
2021-09-06 English
POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON AUGUST 31, 2021
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an announcement of the poll results from an Extraordinary General Meeting (EGM) held on August 31, 2021. It details the voting outcomes on various resolutions related to share option schemes and share awards. The text explicitly states it is announcing the poll results and references the Notice and Circular for full details. There is no substantive financial data or detailed report content, only the voting results. The document length is 9632 characters, which is relatively short and consistent with a voting results announcement rather than a full report. According to the filing definitions and rules, such documents fall under 'Declaration of Voting Results & Voting Rights Announcements' (DVA).
2021-08-31 English
DISCLOSEABLE TRANSACTION ACQUISITION OF RIGHTS RELATING TO EMADINE AND BETOPTIC S IN CHINA
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a discloseable transaction involving the acquisition of rights related to pharmaceutical products Emadine and Betoptic in China. It details an Asset Purchase Agreement between Ocumension Hong Kong and Novartis, including terms, consideration, conditions, and reasons for the acquisition. The document references Listing Rules and percentage ratios relevant to disclosure requirements, indicating it is a regulatory announcement about a transaction rather than a full financial report or earnings release. There is no financial statement or detailed financial analysis present, nor is it a call transcript, management report, or governance document. The content fits the description of a Capital/Financing Update (CAP) as it relates to a significant transaction affecting the company's assets and business operations, specifically an acquisition. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2021-08-24 English
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2021
Interim / Quarterly Report Classification · 95% confidence The document is titled 'INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2021' and contains detailed financial data, business highlights, and management discussion and analysis for the six-month period ending June 30, 2021. It includes unaudited condensed consolidated interim results, revenue figures, loss figures, R&D expenses, and cash balances. The document also discusses pipeline progress and clinical trial updates. The length is about 15,000 characters, indicating a substantive report rather than a brief announcement. The content matches the characteristics of an Interim / Quarterly Report (IR), which provides comprehensive financial data and analysis for a period shorter than a full fiscal year. Therefore, the correct classification is IR with high confidence. H1 2021
2021-08-20 English
VOLUNTARY ANNOUNCEMENT OT-502 APPROVED FOR REAL WORLD STUDY IN HAINAN BOAO
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Ocumension Therapeutics regarding the approval of their product OT-502 for a real world study in Hainan Boao. It provides business updates about product development and regulatory progress but does not contain financial statements, earnings data, or detailed financial analysis. The document is relatively short (2944 characters) and serves as a business update rather than a formal financial report or regulatory filing. It does not announce voting results, management changes, or capital structure changes. It is not a call transcript, audit report, or legal proceeding update. The content fits best as a general regulatory announcement or business update to inform shareholders and investors about recent developments. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2021-08-17 English
COMPLETION OF ISSUE OF UNLISTED WARRANTS UNDER SPECIFIC MANDATE
Capital/Financing Update Classification · 95% confidence The document is an announcement from Ocumension Therapeutics regarding the completion of the issue of unlisted warrants under a specific mandate. It details the terms of the warrant issue, the effect on shareholding structure, and subscription rights. The document is relatively short (4097 characters) and focuses on a capital raising event through warrants issuance, which is a financing activity. There is no detailed financial report or comprehensive financial data presented, nor is it a regulatory certification or voting result. Therefore, this fits best under the category of Capital/Financing Update (CAP).
2021-08-13 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.